Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Receivables (2021 - 2025)

Historic Change in Receivables for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$122160.0.

  • InMed Pharmaceuticals' Change in Receivables fell 8064.59% to -$122160.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $60154.0, marking a year-over-year decrease of 4960.46%. This contributed to the annual value of $114690.0 for FY2025, which is 2407.1% up from last year.
  • InMed Pharmaceuticals' Change in Receivables amounted to -$122160.0 in Q3 2025, which was down 8064.59% from $99715.0 recorded in Q2 2025.
  • InMed Pharmaceuticals' Change in Receivables' 5-year high stood at $207019.0 during Q4 2023, with a 5-year trough of -$165188.0 in Q1 2024.
  • Its 5-year average for Change in Receivables is $20242.6, with a median of $17473.0 in 2022.
  • Examining YoY changes over the last 5 years, InMed Pharmaceuticals' Change in Receivables showed a top increase of 1445156.74% in 2022 and a maximum decrease of 259257.61% in 2022.
  • Over the past 5 years, InMed Pharmaceuticals' Change in Receivables (Quarter) stood at -$638.0 in 2021, then soared by 14451.57% to $91563.0 in 2022, then skyrocketed by 126.09% to $207019.0 in 2023, then tumbled by 110.94% to -$22645.0 in 2024, then plummeted by 439.46% to -$122160.0 in 2025.
  • Its last three reported values are -$122160.0 in Q3 2025, $99715.0 for Q2 2025, and $105244.0 during Q1 2025.